TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03243617

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AO+Mist
Description: Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AO+Mist
Description: Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications
Study: NCT02068924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow freezing versus vitrification

Intervention type: OTHER
Group type: OTHER
Intervention: Slow freezing versus vitrification
Study: NCT03247257

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: Patients will be put under general anesthesia for cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Anesthesia
Description: Patients will receive Epidural Anesthesia for cholecystectomy
Study: NCT02485691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel XRP6258
Description: Pharmaceutical form: solution Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Pharmaceutical form: capsule Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT02864589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered habit reversal training
Description: The I-HRT group will receive a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on habit reversal training (i.e. Woods, D.W. (2008). Managing Tourette syndrome: A behavioral intervention for children and adults therapist guide. OUP, USA.) with added interactive features as videos and illustrations. In short, the participants practice to become more aware of their tics and inhibit them by performing competing responses (movements). The treatment is therapist guided: the participants have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered exposure and response prevention
Description: The I-ERP group receives a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on exposure and response prevention (i.e. Verdellen, C. et al. (2011). Tics: Therapist manual \& workbook for children. Boom, Amsterd.) with added interactive features as videos and illustrations. In short, the participants practice to suppress their tics for longer and longer times, at the same time as premonitory urges are intentionally provoked. The treatment is therapist-guided: the children and parents have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
Study: NCT02376634

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis
Description: Patients will be taught self-hypnosis.
Study: NCT02997501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T790M+ Testing
Description: The patient will need to have T790M+ testing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baseline Visit Blood & Urine Testing
Description: Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baseline ECG
Description: ECG to ensure absence of any cardiac abnormality

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visual Slit-Lamp Testing
Description: Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 Dosing
Description: Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma AZD9291 testing
Description: The patient will need to have plasma AZD9291 testing before treatment
Study: NCT01979367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodyne
Description: Subjects will be treated with MIRE therapy using the Anodyne® device within 72 hours of previous treatments, and in accordance with the Anodyne® package insert indications for use 30 to 45 minutes professional units on power setting of 8,. In addition, patients will undergo TENS therapy with the use of either the Avazzia® Pro Sport or TENS 3000 (for no less than 30 mins, both on label) in accordance with the indications for use of each TENS device, for a minimum of 15 minutes at the subjective site for pain and each vertebrae nerve base, when impairment is confirmed with the objective Small Pain Fiber (SPF) Nerve Conduction Study (NCS) test performed.
Study: NCT02567981

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 21 micronutrient-fortified supplement
Description: 21 micronutrient fortified supplement: Dose: 18.75g/day. Contains the following daily amounts per dose: Zinc 9 mg, Copper 300mcg, Iron 12mg, Vitamin D 5 mcg, Folic Acid 160mcg, Vitamin E 5mg, Iodine 90mcg, Calcium 200mg, Vitamin A 250mg, Phosphorus 150 mg, Vitamin C 40mg, Magnesium 40mg, Vitamin B12 0.9mcg, Selenium 17mcg, Thiamine 0.5mg, Manganese 0.17mg, Niacin 6mg, Biotin 8mg, Riboflavin 0.5mg, Vitamin B5 1.8mg, Vitamin B6 0.5 mg. Formula (percentage by weight): Maize 64.08%, Soy Beans 30%, Vitamins and Minerals 5.92%, BHA 0.006%. Energy: 73kcal, Protein 4g, Fat 1g, Dietary Fiber 2g, Carbohydrates 12g.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cereal Fortificado (Fortified Cereal)
Description: Cereal Fortificado Dose: 45g/day. Contains the following daily amounts per dose: Vitamin A 226.6mcg, Thiamine 0.058mg, Riboflavin 0.202mg, Niacin 2.16mg, Panthotenic acid 3.015mg, Vitamin B6 0.765mg, Folate 27mcg, Vitamin B12 0.9mg, Vitamin C 45mg, Vitamin D 1.8mcg, Vitamin E 3.735mg, Vitamin K 45mcg, iron 3.6mg, Zinc 1.8mg, Iodine 18mcg, potassium 180mg, phosphorus 90 mg, calcium 58.50mg. Percentage weight: 58% corn, 20% soy, Skim dry milk 8%, Sugar 9%, Soy Oil 3%, Vitamins and Minerals 0.2%, calcium phosphate 1.23%, Potassium chloride 0.27%. Energy 184.5 kcal, protein 7.2%, Fat 4.1%, Fiber 1.4%, Ash 4.6%.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulphate
Description: Ferrous sulfate drops children \<12 months: 12,5mg elemental iron/day (continuous). Children from 12-23.9months: elemental iron 25mg/day (continuous).~Chidlren from 24 to 59 months: 1ml/day for two months, every 6 months.
Study: NCT03071367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Simulation
Study: NCT03408561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive message via Twitter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT02011373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fixation technique using a sterile synthetic liquid tissue glue: IFABOND™
Study: NCT02274974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: •The wound of C.Swill be infiltrated before closure of the skin, with 20 ml of 2% lidocaine.
Study: NCT02567981

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: Vitamin A Capsules: children \<12 months: 100.000 IU/6 months. Children 12-59 months: 200.000 IU/6 months.
Study: NCT03991845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit D
Description: Vit D supplementation was done
Study: NCT02274974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine and Epinephrine
Description: The wound of C.S will be infiltrated before closure of the skin, with 20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000.
Study: NCT02730598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Training System (HTS)
Description: Electrodes (15 cm x 6 cm) will be placed over the quadriceps and electrodes (11 cm x 6 cm) (Sekisui Plastics Co., Tokyo, Japan) will be placed over the hamstrings. Electrical stimulation parameters will be based on a standard Russian waveform in which a 5,000 Hz carrier frequency is modulated at 40 Hz (2.4 ms on, 22.6 ms off) to deliver a rectangular voltage biphasic pulse. Acceleration sensors as a joint motion sensor (EWTS9PD, Home Appliances Development Center Corporate Engineering Division, Appliances Company Panasonic Corporation 2-3-1-2 Noji-higashi,Kusatsu City, Shiga, Japan) is placed on the front of each leg 88mm above the patellar edge. It analyzes the algorithm of each exercise pattern, and stimulates the antagonist of the motion of each bilateral knee joint during exercise. Electrical stimulation intensity will be set to \~50-60% of 1RM based on the subject's tolerance. The subject's tolerance gradually increases, and electrical stimulation intensity is reset every 2 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensory TENS
Description: The electrical stimulation intensity will be set under the muscle contraction threshold (but at a level at which the subject can perceive as sensory TENS). Electrical stimulation parameters (i.e. waveform and pulse duration) will be the same of HTS, while the amplitude will be lower. The subject will be stimulated using the same device as for HTS.
Study: NCT03991845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit D
Description: Vit D supplementation was done
Study: NCT04632888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone support for breastfeeding follow-up
Description: The researcher, after the mother is discharged, by making a video call by phone every day for the first week, providing counseling to the mother on matters that she needs and recording it in the Baby Monitoring Form The researcher gives the mother a video
Study: NCT02677935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community education programs
Study: NCT00874146

Intervention type: GENETIC
Intervention: Fluorescent in-situ hybridization (FISH)
Description: Dual color FISH test to assess ratio of HER2/neu amplification
Study: NCT02659800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04018053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine
Description: 18F-fluciclovine is a new radiotracer. This radiotracer targets amino-acid transporters, which are overexpressed in multiple cancers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
Study: NCT02659800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Given IM
Study: NCT01843036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Durham Connects
Description: Durham Connects begins with a visit during the birthing hospital stay, followed by 1-3 nurse home visits between 4-12 weeks of infant age, and then a follow-up contact one month later. During the visits, the nurse engages with the mother and completes a health and psychosocial assessment, during which she systematically assesses risk and family needs in 12 important empirically-derived areas of family functioning across 4 domains (i.e. - healthcare, parenting/childcare, family violence/safety, and maternal well-being). For each domain found to be at risk, the nurse intervenes directly to support the mother (mild risk) or connects the mother with matched community resources as needed to address individualized long-term family needs (moderate or severe risk).
Study: NCT02922725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-hydroxytryptophan and Creatine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Study: NCT04434417

Intervention type: DEVICE
Intervention: 2019-nCoV IgG/IgM Rapid Test Cassette
Description: The specimen (whole blood, serum, plasma) will be loaded into the cassette and will migrate via capillary action along the membrane to react with the gold conjugate. The result will be available in 10 minutes
Study: NCT03925623

Intervention type: OTHER
Intervention: Novel approaches for the design of child resistant closures
Description: Two novel designs for child resistant closures are tested.~One is sized based on the anthropometric properties of adults and children's hands such that it should disallow children from engaging the system and enable adults (the physically based design strategy). The other replicates the first design, but is sized such that either of the two populations should be able to engage the closure.~In testing this way, we begin to differentiate the paradigm that holds the children out (the cognitively based design strategy-- they do not understand and/or a physical one- they are unable to use the closure).~Results (proportion of children opening within the first or second five minute periods of test and time to opening during the same) from each of these, will be compared to results from the third treatment, a standard, commercially available push and turn system.

Intervention type: OTHER
Intervention: Novel approaches for the design of child resistant closures
Description: Two novel designs for child resistant closures are tested.~One is sized based on the anthropometric properties of adults and children's hands such that it should disallow children from engaging the system and enable adults (the physically based design strategy). The other replicates the first design, but is sized such that either of the two populations should be able to engage the closure.~In testing this way, we begin to differentiate the paradigm that holds the children out (the cognitively based design strategy-- they do not understand and/or a physical one- they are unable to use the closure).~Results (proportion of children opening within the first or second five minute periods of test and time to opening during the same) from each of these, will be compared to results from the third treatment, a standard, commercially available push and turn system.
Study: NCT02659800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given IM
Study: NCT01224392

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with boost
Description: Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
Study: NCT02434068

Intervention type: OTHER
Intervention: CT
Description: followup
Study: NCT00642733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 100mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000mg/m2 iv weekly for 8 weeks, then weekly for 3 weeks of each 4 week cycle
Study: NCT00218660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 150mg/day Naltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 150mg/day Naltrexone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRENDA
Description: Psychosocial Treatment

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BRENDA
Description: Psychosocial Treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Cognitive Behavioral Therapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT
Description: Cognitive Behavioral Therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03925623

Intervention type: OTHER
Intervention: Novel approaches for the design of child resistant closures
Description: Two novel designs for child resistant closures are tested.~One is sized based on the anthropometric properties of adults and children's hands such that it should disallow children from engaging the system and enable adults (the physically based design strategy). The other replicates the first design, but is sized such that either of the two populations should be able to engage the closure.~In testing this way, we begin to differentiate the paradigm that holds the children out (the cognitively based design strategy-- they do not understand and/or a physical one- they are unable to use the closure).~Results (proportion of children opening within the first or second five minute periods of test and time to opening during the same) from each of these, will be compared to results from the third treatment, a standard, commercially available push and turn system.
Study: NCT01121796

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water or milk

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D enriched milk
Study: NCT01736111

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: one way text

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal feedback
Study: NCT03007550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic total gastrectomy
Description: LTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open total gastrectomy
Description: OTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
Study: NCT01071044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine Dimesylate
Description: Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 30, 50 or 70 mg
Description: Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
Study: NCT00218660

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo